Sanofi SA

$ 42.58 0 (0%)
Volume: 695,699 Avg Vol (1m): 1,316,298
Market Cap $: 106.47 Bil Enterprise Value $: 128.81 Bil
P/E (TTM): 26.83 P/B: 1.70
Earnings Power Value 21.8
Net Current Asset Value -12.84
Tangible Book -3.19
Projected FCF 44.06
Median P/S Value 41.64
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.25
Cash-To-Debt range over the past 10 years
Min: 0.14, Med: 0.4, Max: 10.62
Current: 0.25
0.14
10.62
Equity-to-Asset 0.51
Equity-to-Asset range over the past 10 years
Min: 0.48, Med: 0.58, Max: 0.65
Current: 0.51
0.48
0.65
Debt-to-Equity 0.47
Debt-to-Equity range over the past 10 years
Min: 0.05, Med: 0.25, Max: 0.52
Current: 0.47
0.05
0.52
Debt-to-EBITDA 2.65
Debt-to-EBITDA range over the past 10 years
Min: 0.7, Med: 1.49, Max: 2.7
Current: 2.65
0.7
2.7
Interest Coverage 14.29
Interest Coverage range over the past 10 years
Min: 8, Med: 11.91, Max: 22.98
Current: 14.29
8
22.98
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.64
DISTRESS
GREY
SAFE
Beneish M-Score -2.49
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 8.33%
WACC 2.54%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 18.54
Operating Margin range over the past 10 years
Min: 17.86, Med: 21.31, Max: 24.94
Current: 18.54
17.86
24.94
Net Margin % 9.73
Net Margin range over the past 10 years
Min: 9.73, Med: 13.66, Max: 23.24
Current: 9.73
9.73
23.24
ROE % 6.26
ROE range over the past 10 years
Min: 6.26, Med: 8.38, Max: 14.56
Current: 6.26
6.26
14.56
ROA % 3.21
ROA range over the past 10 years
Min: 3.21, Med: 4.71, Max: 8.23
Current: 3.21
3.21
8.23
ROC (Joel Greenblatt) % 29.23
ROC (Joel Greenblatt) range over the past 10 years
Min: 29.23, Med: 44.95, Max: 56.76
Current: 29.23
29.23
56.76
3-Year Total Revenue Growth Rate 0.80
3-Year Revenue Growth Rate range over the past 10 years
Min: -3.5, Med: 6, Max: 27.4
Current: 2.5
-3.5
27.4
3-Year Total EBITDA Growth Rate -3.30
3-Year EBITDA Growth Rate range over the past 10 years
Min: -6.3, Med: 2, Max: 35.5
Current: -1.6
-6.3
35.5
3-Year EPS w/o NRI Growth Rate 1.00
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -13.4, Med: 1, Max: 41.7
Current: 1
-13.4
41.7

Ratios

Current vs industry vs history
PE Ratio (TTM) 26.92
PE Ratio range over the past 10 years
Min: 9.55, Med: 20.21, Max: 32.04
Current: 26.92
9.55
32.04
Forward PE Ratio 13.09
N/A
PE Ratio without NRI 26.83
PE without NRI range over the past 10 years
Min: 11.06, Med: 21.45, Max: 32.66
Current: 26.83
11.06
32.66
Price-to-Owner-Earnings 19.98
Price-to-Owner-Earnings range over the past 10 years
Min: 7.31, Med: 13.32, Max: 21.33
Current: 19.98
7.31
21.33
PB Ratio 1.70
PB Ratio range over the past 10 years
Min: 1.16, Med: 1.61, Max: 2.33
Current: 1.7
1.16
2.33
PS Ratio 2.70
PS Ratio range over the past 10 years
Min: 1.8, Med: 2.64, Max: 4.12
Current: 2.7
1.8
4.12
Price-to-Free-Cash-Flow 26.98
Price-to-Free-Cash-Flow range over the past 10 years
Min: 7.49, Med: 15.52, Max: 27.97
Current: 26.98
7.49
27.97
Price-to-Operating-Cash-Flow 17.36
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 6.08, Med: 11.69, Max: 18
Current: 17.36
6.08
18
EV-to-EBIT 30.68
EV-to-EBIT range over the past 10 years
Min: 9.6, Med: 16.8, Max: 30.68
Current: 30.68
9.6
30.68
EV-to-EBITDA 11.54
EV-to-EBITDA range over the past 10 years
Min: 5.1, Med: 9.9, Max: 14.6
Current: 11.54
5.1
14.6
EV-to-Revenue 3.16
EV-to-Revenue range over the past 10 years
Min: 1.9, Med: 2.9, Max: 4.4
Current: 3.16
1.9
4.4
Shiller PE Ratio 18.17
Shiller PE Ratio range over the past 10 years
Min: 14.64, Med: 19.14, Max: 27.29
Current: 18.17
14.64
27.29
Current Ratio 1.32
Current Ratio range over the past 10 years
Min: 0.79, Med: 1.63, Max: 2.71
Current: 1.32
0.79
2.71
Quick Ratio 0.88
Quick Ratio range over the past 10 years
Min: 0.59, Med: 1.14, Max: 2.41
Current: 0.88
0.59
2.41
Days Inventory 244.95
Days Inventory range over the past 10 years
Min: 183.78, Med: 217.06, Max: 244.95
Current: 244.95
183.78
244.95
Days Sales Outstanding 71.77
Days Sales Outstanding range over the past 10 years
Min: 69.78, Med: 76.56, Max: 83.73
Current: 71.77
69.78
83.73
Days Payable 160.53
Days Payable range over the past 10 years
Min: 104.92, Med: 125.26, Max: 160.91
Current: 160.53
104.92
160.91

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 4.09
Trailing Dividend Yield range over the past 10 years
Min: 2.83, Med: 3.96, Max: 5.24
Current: 4.09
2.83
5.24
Dividend Payout Ratio 1.09
Dividend Payout Ratio range over the past 10 years
Min: 0.55, Med: 0.86, Max: 1.09
Current: 1.09
0.55
1.09
3-Year Dividend Growth Rate (Per Share) 2.10
3-Year Dividend Growth Rate range over the past 10 years
Min: -15.6, Med: 6.5, Max: 37.9
Current: 2.1
-15.6
37.9
Forward Dividend Yield % 4.09
N/A
Yield-on-Cost (5-Year) % 4.49
Yield-on-Cost (5y) range over the past 10 years
Min: 3.11, Med: 4.35, Max: 5.76
Current: 4.49
3.11
5.76
3-Year Share Buyback Rate 1.50
3-Year Share Buyback Rate range over the past 10 years
Min: -24.5, Med: 0.5, Max: 2.1
Current: 1.5
-24.5
2.1

Valuation & Return

Current vs industry vs history
Price-to-Median-PS-Value 1.02
Price-to-Median-PS-Value range over the past 10 years
Min: 0, Med: 1.11, Max: 8.74
Current: 1.02
0
8.74
Earnings Yield (Joel Greenblatt) % 3.26
Earnings Yield (Greenblatt) range over the past 10 years
Min: 3.26, Med: 6, Max: 10.5
Current: 3.26
3.26
10.5
Forward Rate of Return (Yacktman) % 5.38
Forward Rate of Return range over the past 10 years
Min: 1, Med: 6, Max: 19.2
Current: 5.38
1
19.2

» SNY's 30-Y Financials

Financials (Next Earnings Date: 2020-02-07)

» Interactive Chart

Peter Lynch Chart

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:SNY

Business Description

Industry Drug Manufacturers » Drug Manufacturers    NAICS : 325412    SIC : 2834
Compare NYSE:LLY LSE:GSK NAS:AMGN NYSE:ABBV LSE:AZN NAS:GILD NYSE:BMY NAS:CELG XTER:BAYN NAS:BIIB TSE:4519 TSE:4568 TSE:4503 XMAD:GRF.P TSE:4578 HKSE:01093 SHSE:600436 MIL:REC TSE:4528 TSE:4151
Traded in other countries SANO.Austria SAN.France SNW.Germany SANF.Italy SNYN.Mexico SAN.Switzerland 0O59.UK
Address 54, Rue La Boétie, Paris, FRA, 75008
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing just over 10% of total sales. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent most of the remainder of sales.

More Statistics

Revenue (TTM) (Mil) $ 41,687.2
EPS (TTM) $ 1.62
Beta 0.44
Volatility % 13.86
52-Week Range $ 40 - 45.62
Shares Outstanding (Mil) 2,490.91

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y